Biodesix Inc. (BDSX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Biodesix Inc. (BDSX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.15

-0.09 (-7.26%)

At close: Jan 14, 2025, 3:59 PM

1.14

-0.44%

After-hours Jan 14, 2025, 07:53 PM EST

undefined% (undefined)

Bid	0.45
Market Cap	166.56M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.37
PE Ratio (ttm)	-3.09
Forward PE	n/a
Analyst	Buy

Ask	1.48
Volume	455,532
Avg. Volume (20D)	443,734
Open	1.25
Previous Close	1.24
Day's Range	1.13 - 1.26
52-Week Range	1.11 - 2.21
Beta	undefined

About BDSX

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. ...

[Show more]

Industry Medical - Diagnostics & Research

Sector Healthcare

IPO Date Oct 28, 2020

Employees 217

Stock Exchange NASDAQ

Ticker Symbol BDSX

Website https://www.biodesix.com

Analyst Forecast

According to 4 analyst ratings, the average rating for BDSX stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 162.01% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Biodesix Inc. is scheduled to release its earnings on Feb 28, 2025, before market opens.
Analysts project revenue of $19.83M, reflecting a 35.19% YoY growth and earnings per share of -0.06, making a -40.00% decrease YoY.

Why Price Moved

2 months ago · Source

-23.53%

Biodesix shares are trading lower after the compan... Unlock content with Pro Subscription

9 months ago · Source

-7.28%

Biodesix shares are trading lower after the company announced pricing of its oversubscribed and upsized underwritten offering of common stock and concurrent private placement.

News

1 week ago · zacks.com

BDSX Stock Rises After Publication of Study Data for Nodify CDT Test

Biodesix announces positive study data for its Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal.

1 month ago · zacks.com

Biodesix (BDSX) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Biodesix (BDSX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i...

2 months ago · seekingalpha.com

Biodesix, Inc. (BDSX) Q3 2024 Earnings Call Transcript

Biodesix, Inc. (NASDAQ:BDSX ) Q3 2024 Earnings Conference Call November 1, 2024 8:30 AM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper C...

2 months ago · zacks.com

Biodesix, Inc. (BDSX) Reports Q3 Loss, Misses Revenue Estimates

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.12 per share a year ago.

2 months ago · businesswire.com

Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024

LOUISVILLE, Colo.--(BUSINESS WIRE)--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the t...